Nettet4. jun. 2024 · Intellia’s global Phase 1 trial is an open-label, multi-center, two-part study of NTLA-2001 in adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). The trial’s primary... NettetPosted 5:10:54 PM. Why Join Intellia?Our mission is to develop curative genome editing treatments that can positively…See this and similar jobs on LinkedIn.
Intellia Therapeutics Announces Proposed Public Offering of …
Nettet1. des. 2024 · CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering of … Nettet26. jun. 2024 · Intellia is enrolling adults between 18 to 80 years old with inherited ATTR and symptoms of nerve damage. Some, not all, have heart damage. They'll be tracked for two years. The results published in NEJM, which are also being presented at a medical conference on Saturday, are from three patients who received a low dose and three … tata sir
Intellia Therapeutics Announces Pricing of Public Offering of …
Nettet5. jul. 2024 · CAMBRIDGE, Mass. - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced the closing of an underwritten public offering of 4,758,620 shares of its common stock, including the … Nettet3. mar. 2024 · Intellia Therapeutics. Market Cap. $3B. Today's Change. (0.47%) $0.17. Current Price. $35.96. Price as of April 6, 2024, 10:00 a.m. ET. You’re reading a free … Nettet30. nov. 2024 · November 30, 2024 - 9:28 pm. CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an … 31歳 平均年収 男性